Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
Recruiting
- Conditions
- Adjuvant Chemotherapy
- Registration Number
- NCT06389552
- Lead Sponsor
- HK inno.N Corporation
- Brief Summary
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
- Detailed Description
This study is multi-center, prospective, long-term follow-up observational study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Age over 19 at the time of obtaining the informed consent form
- Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
- ECOG 0 or 1
- Scheduled to RO or R1 resection
- Organ function capable of chemotherapy
Exclusion Criteria
- FOLFIRINOX contraindications among the drug approval requirements
- Palliative Therapy
- Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival Day 1 to Week 88 Duration of survival before pancreatic cancer recurrence or death
- Secondary Outcome Measures
Name Time Method Overall survival Day 1 to Week 88 Duration of overall survival
Trial Locations
- Locations (1)
Seoul ST. Mary's Hospital
🇰🇷Seoul, Korea, Republic of